Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
The six-part webinar series aims to enhance awareness, diagnosis, and management of autoimmune diseases
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The PIPE offering consists of 36,190,476 units
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
Subscribe To Our Newsletter & Stay Updated
